Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment

PLoS Computational Biology

Volumn 9, Issue 5, 2013, Pages

  Pandey, Gouri Shankar ^a   Yanover, Chen ^b,d   Howard, Tom E ^c   Sauna, Zuben E ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d IBM HAIFA RESEARCH LAB   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BINDING ENERGY; COMPLEX NETWORKS; GENES; RISK ASSESSMENT; RISK PERCEPTION; T-CELLS;

CLASS II; EFFECTIVE MANAGEMENT; FACTOR VIII; HAPLOTYPES; HEMOPHILIA A; HUMAN POPULATION; PROTEIN THERAPEUTICS; RISK FACTORS; SINGLE NUCLEOTIDE POLYMORPHISMS; WILD TYPES;

PEPTIDES;

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SYNTHETIC PEPTIDE;

ALLELE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; F8 GENE; GENE FREQUENCY; HAPLOTYPE; HEMOPHILIA A; HUMAN; MATHEMATICAL COMPUTING; MISSENSE MUTATION; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 84878506071     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003066     Document Type: Article

References (30)

1. Mannucci PM, Tuddenham EGD, (2001) Medical progress- The hemophilias- From royal genes to gene therapy. New Engl J Med 344: 1773-1779.
2. Lillicrap D, (2010) Improvements in factor concentrates. Curr Opin Hematol 17: 393-397.
3. Lacroix-Desmazes S, Navarrete AM, Andre S, Bayry J, Kaveri SV, et al. (2008) Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 112: 240-249.
4. Zhang AH, Skupsky J, Scott DW, (2009) Factor VIII Inhibitors: Risk Factors and Methods for Prevention and Immune Modulation. Clin Rev Allergy Immunol 37: 114-124.
5. Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, et al. (2009) Inhibitors of Factor VIII in Black Patients with Hemophilia. New Engl J Med 360: 1618-1627.
6. Viel KR, Machiah DK, Warren DM, Khachidze M, Buil A, et al. (2007) A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 109: 3713-3724.
7. Bray GL, Kroner BL, Arkin S, Aledort LW, Hilgartner MW, et al. (1993) Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol 42: 375-379.
8. Qian J, Collins M, Sharpe AH, Hoyer LW, (2000) Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 95: 1324-1329.
9. Gouw SC, van den Berg HM, Oldenburg J, Astermark J, de Groot PG, et al. (2012) F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 119: 2922-2934.
10. Astermark J, Lacroix-Desmazes S, Reding MT, (2008) Inhibitor development. Haemophilia 14 Suppl 3: 36-42.
11. Jacquemin M, Vantomme V, Buhot C, Lavend'homme R, Burny W, et al. (2003) CD4(+) T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 101: 1351-1358.
12. Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM, (1995) Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin. Thromb Haemost 74: 619-621.
13. Fijnvandraat K, Turenhout EA, van Den Brink EN, ten Cate JW, van Mourik JA, et al. (1997) The missense mutation Arg593→Cys is related to antibody formation in a patient with mild hemophilia A. Blood 89: 4371-4377.
14. Peerlinck K, Jacquemin MG, Arnout J, Hoylaerts MF, Gilles JG, et al. (1999) Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 93: 2267-2273.
15. Gilles JG, Lavend'homme R, Peerlinck K, Jacquemin MG, Hoylaerts M, et al. (1999) Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes. Thromb Haemost 82: 40-45.
16. James EA, van Haren SD, Ettinger RA, Fijnvandraat K, Liberman JA, et al. (2011) T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site. J Thromb Haemost 9: 689-699.
17. Singh H, Raghava GP, (2001) ProPred: prediction of HLA-DR binding sites. Bioinformatics 17: 1236-1237.
18. Nielsen M, Lund O, Buus S, Lundegaard C, (2010) MHC class II epitope predictive algorithms. Immunology 130: 319-328.
19. Wang P, Sidney J, Dow C, Mothe B, Sette A, et al. (2008) A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 4: e1000048.
20. Mallios RR, (2001) Predicting class II MHC/peptide multi-level binding with an iterative stepwise discriminant analysis meta-algorithm. Bioinformatics 17: 942-948.
21. Lanzavecchia A, Reid PA, Watts C, (1992) Irreversible association of peptides with class II MHC molecules in living cells. Nature 357: 249-252.
22. Hall FC, Rabinowitz JD, Busch R, Visconti KC, Belmares M, et al. (2002) Relationship between kinetic stability and immunogenicity of HLA-DR4/peptide complexes. Eur J Immunol 32: 662-670.
23. Lazarski CA, Chaves FA, Jenks SA, Wu SH, Richards KA, et al. (2005) The kinetic stability of MHC class II: Peptide complexes is a key parameter that dictates immunodominance. Immunity 23: 29-40.
24. Constant SL, Bottomly K, (1997) Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 15: 297-322.
25. Baumgartner CK, Ferrante A, Nagaoka M, Gorski J, Malherbe LP, (2010) Peptide-MHC class II complex stability governs CD4 T cell clonal selection. J Immunol 184: 573-581.
26. Nielsen M, Lundegaard C, Blicher T, Peters B, Sette A, et al. (2008) Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol 4: e1000107.
27. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, et al. (1993) Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74: 929-937.
28. Steinitz KN, van Helden PM, Binder B, Wraith DC, Unterthurner S, et al. (2012) CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice. Blood 119: 4073-4082.
29. Burrows JM, Wynn KK, Tynan FE, Archbold J, Miles JJ, et al. (2007) The impact of HLA-B micropolymorphism outside primary peptide anchor pockets on the CTL response to CMV. Eur J Immunol 37: 946-953.
30. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S, (2010) NetMHCIIpan-2.0- Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 6: 9.